The liver is the most important organ for the biotransformation of xenobiotics, and the failure to treat acute or acute-on-chronic liver failure causes high mortality rates in affected patients. Due to the lack of donor livers and the limited possibility of the clinical management there has been growing interest in the development of extracorporeal liver support systems as a bridge to liver transplantation or to support recovery during hepatic failure. Earlier attempts to provide liver support comprised non-biological therapies based on the use of conventional detoxification procedures, such as filtration and dialysis. These techniques, however, failed to meet the expected efficacy in terms of the overall survival rate due to the inadequate support of several essential liver-specific functions. For this reason, several bioartificial liver support systems using isolated viable hepatocytes have been constructed to improve the outcome of treatment for patients with fulminant liver failure by delivering essential hepatic functions. However, controlled trials (phase I/II) with these systems have shown no significant survival benefits despite the systems' contribution to improvements in clinical and biochemical parameters. For the development of improved liver support systems, critical issues, such as the cell source and culture conditions for the longterm maintenance of liver-specific functions in vitro, are reviewed in this article. We also discuss aspects concerning the performance, biotolerance and logistics of the selected bioartificial liver support systems that have been or are currently being preclinically and clinically evaluated.
Introduction
The liver as the central metabolic organ is responsible for many physiological functions, including detoxification and biotransformation. Therefore, acute liver failure often compromises multiple organs leading to the death of affected patients (Muto et al. 1988; Hughes et al. 1998) . Despite the intensive medical care, the mortality of hepatic failure is still high, and its clinical management, therefore, remains a challenge (Rahman and Hodgson 2001) . One of the main characteristics of the liver is its capacity to regenerate. In acute hepatic failure, the liver often retains its regenerative ability. By contrast, this feature is hardly observed, if at all, in chronic liver failure (Koniaris et al. 2003; Black et al. 2004) . In this case, the transplantation is the only life extending method. However, liver transplantation is beset by a scarcity of donor livers and a lack of immediate availability (Lee 1993; van de Kerkhove et al. 2004) . In order to circumvent this problem, alternative methods have been developed to stabilize the conditions of patients with hepatic failure until the regeneration of the liver or availability of the donor organ (Rifai et al. 2003) . Several extracorporeal detoxification systems, such as hemodialysis, hemofiltration, adsorption, plasma exchange, and plasma perfusion, to support liver functions have been clinically tested with varying success (McLaughlin et al. 1999) . Since the liver commands a myriad of functions, including hormonal regulation, biotransformation and detoxification, protein synthesis, lipid and glucose metabolism, production of bile components, as well as pH regulation (Kmiec´2001), complex biochemical pathways exist that cannot be simply replaced by these non-biological liver support systems. From a medical point of view, the purely detoxifying and filtrating capacity of anorganic devices has been a relevant addition to the treatment regimens. Apart from charcoal-and polymer-based regimens, the use of albumin as a carrier and shuttle molecule was also proven to be a successful treatment option, which is currently in widespread use, such as the molecular adsorbent recirculation system (MARS) (Mitzner et al. 2001) and the more recent addition to the field, namely the Prometheus system (Evenepoel et al. 2005) . Both systems replace the detoxification function of the liver by removing of a number of toxins. Comparison of these systems has shown that Prometheus treatment resulted in significant better reduction ratios of bilirubin, ammonia and urea (Krisper et al. 2005) . However, both systems cannot reflect the full synthetic, metabolic and regulatory functions of the liver parenchyma. For this reason, new bioartificial systems have been developed that contrary to the classic systems include a cellular hepatic component. These biological systems are believed to be more likely to provide many essential hepatic functions, namely detoxification, metabolism, and biosynthesis, than the techniques based on the non-biological liver support.
Anatomy of the liver
In the liver, parenchymal hepatocytes are in functional contact with non-parenchymal cells, including bile duct cells, sinusoidal endothelial cells, Kupffer cells, stellate cells (fat storing Ito cells) and Pit cells (Figure 1 ). The assembly of the hepatic sinusoidal cells points to the functional interaction between parenchymal and non-parenchymal cells. Sinusoidal endothelial cells differ from other endothelial cells by the lack of a subjacent basal lamina (De Leeuw et al. 1990; Wake 1999) . These cells have a scavenger function by eliminating macromolecules through endocytosis (Elvevold et al. 2004; Enomoto et al. 2004) . They form fenestrae to filter fluids, dissolved substances and particles from serum which are then adsorbed and metabolized by hepatocytes. Bile canaliculi are located on the lateral surface of adjoining hepatocytes. Both parenchymal and non-parenchymal cells are embedded in an extracellular matrix consisting of collagen I, III, IV and V, laminin, fibronectin, tenascin, nidogen and the glycoprotein SPARC (Secreted Protein Acidic and Rich in Cysteine) (Martinez-Hernandez and Amenta 1993).
Function of hepatocytes and requirements on bioartificial liver support systems
Most of the biochemical functions are carried out by mature hepatocytes (Kmiec´2001). Fulminant hepatic failure is a consequence of the loss of normal liver function and often occurs as a result of autoimmune and viral hepatitis, hepatocellular cancer, exposure to toxins such as alcohol and drugs, or trauma (Gimson 1996) . The concept of a bioartificial liver support system is based on the assumption that only hepatocytes perform a wide range of liver-specific functions, and it uses primary hepatocytes or a hepatoma cell line due to their expression of highly differentiated functions (Sauer et al. 2001) . For the development of such a liver support system, special attention has been paid to providing the architectural basis for the reconstruction of a proper cellular microenvironment that ensures the highest and prolonged functional activity of the hepatocytes. The main problem of such systems is their biotolerance in terms of the duration of the treatment because of the possible immune reaction provoked by a direct contact between animal (xenogeneic) hepatocytes and the recipient's blood or plasma as observed with porcine liver cells (Hasegawa et al. 1999) . Therefore, it is crucial for successful long-term stable hepatocyte cultivation in a bioartificial system that the cells are protected from the host immune system. Additionally, adequate oxygenation and nutrient supply are particularly critical factors in terms of maintaining hepatocyte viability and function (McClelland et al. 2003) . These parameters have been improved to provide hepatocytes an in vivo-like environment in bioartificial liver support systems (Gerlach 1996; De Bartolo and Bader 2001) . Furthermore, logistical aspects such as storage, transportation and scale-up of the systems have still to be optimized to offer flexible and independent devices for the effective clinical application.
Cell source
Biological systems have focused in the past on maintaining xenogeneic, allogeneic primary hepatocytes, or human cell lines alive within the respective liver support systems. On the basis of results from human liver resections, at least 20% of the liver mass may be required for adequate liver support (Morsiani et al. 2002a ). According to a theoretical calculation, an adequate mass of up to at least 1-2 · 10 10 viable hepatocytes is necessary to maintain normal human liver function and is needed in a liver support system to treat patients with liver failure (Morsiani et al. 2002a; van de Kerkhove et al. 2005b ). The methods used for isolation of primary human hepatocytes are less than optimal because of the limited number of donor organs (Dou et al. 1992; Runge et al. 2000) . Therefore, other cell sources, including animal (xenogeneic) hepatocytes, hepatoblastoma cell lines, and immortalized hepatocytes have been used for their application in bioartificial liver support systems (Tsiaoussis et al. 2001 ). However, a concern with the use of hepatic tumor cell lines, e.g. HepG2, is the possible risk in the transmission of potentially tumorigenic cells to patients (Louha et al. 1997) . Instead, primary human and xenogeneic hepatocytes are used in bioartificial systems which have been or are currently in various stages of clinical evaluation. Gerlach et al. have used human hepatocytes obtained from donor organs that are unsuitable for liver transplantations ). However, due to a lack of human organ availability the current main source of hepatocytes for bioartificial systems is xenogeneic material. Primary porcine hepatocytes have preferably been used as the xenograft candidates regarding differentiated metabolic functions and high-yield retrieval (Sielaff et al. 1995; te Velde et al. 1995; Gregory et al. 2000) . Preparation of hepatocytes from pig liver has been shown to deliver a sufficient amount of cells for a bioartificial system (De Bartolo and Bader 2001) . However, clinical application of xenogeneic hepatocytes has become a controversial issue with regard to xenotransplantation-associated problems. Porcine xenografts, for example, elicit a severe humoral and cellular immunologic response in humans due to the presence of the carbohydrate Gala (1-3)Gal epitope on pig cells, thereby compromising the functionality of the bioartificial liver (Baquerizo et al. 1999; van de Kerkhove et al. 2005a) . Besides these immunological problems, proteins released by porcine hepatocytes do not carry out the same functions as their human counterparts. Another possible risk is the transfer of viral pathogens from the xenograft donor to the recipient (Fishman and Patience 2004) . To date, several potentially pathogen viruses have been identified, among which are porcine endogenous retrovirus (PERV), porcine cytomegalovirus (PCMV), and porcine lymphotropic herpesvirus (PLHV). In order to prevent a viral infection in patients, hepatocytes from SPF (specific pathogen free) animals which are raised under strictly controlled conditions may probably be one of the best xenograft candidates . However, since PERV genomes are present in all porcine cells (Blusch et al. 2002) , transmission of this virus from SPF animals to recipients cannot be excluded. Interestingly, PERV transmission into humans has never been observed in vivo (Pitkin and Mullon 1999; Irgang et al. 2003) . Nevertheless, further interest has developed in finding new cell sources for bioartificial support systems, as well as for transplantations. Human liver cells, that have been immortalized using different systems, have been suggested as an interesting cell source. The immortalized human cell line HepZ, for example, was obtained by transfecting the cells from human liver biopsy with the plasmids containing the albumin-promotor-regulated antisense constructs against the negative controlling cell cycle proteins Rb and p53 (Werner et al. 1999 ). The cells were co-transfected with plasmids harboring genes coding for the cellular transcription factor E2F and D1 cyclin to overcome the G1-restriction point. Moreover, Kobayashi et al. have established the Cre-loxP recombination system that targets cells in their final differentiated state (Kobayashi et al. 2003) . This system uses a retroviral vector expressing the immortalizing gene simian virus 40 large T-antigen (SV40Tag) which, in turn, is located between loxP sequences (consensus 34 bp DNA recognition sites). This gene can be removed by the Cre recombinase-mediated reaction (Cre-loxP reaction) (Nagy 2000) . These and other so far established immortalized human hepatocyte cell lines have been shown to vary in their tumorigenicity and hepatic functions (Hoekstra and Chamuleau 2002) . Although immortalized cells have the capacity to be both highly proliferative and differentiated, they tend to lose critical functions, e.g. drug and ammonia metabolism, in vitro compared with primary counterparts, thereby limiting their application in the support system (Cascio 2001) . Furthermore, comparison of primary human hepatocytes and the hepatoma cell line (HepG2) has shown that the former are more suitable for the development of liver support systems with respect to their biotransfomation properties (Wilkening et al. 2003) . Expansion of autologous hepatocytes in patients with liver disease is not advantageous for at least the following five reasons: (i) The underlying disease, i.e. liver carcinoma or hepatitis, could be transmitted to the liver support system; (ii) Liver failure is an acute phenomenon, and creating a liver mass of several grams in vitro would require plenty of time; (iii) Removing healthy liver tissue from an impaired patient in a critical situation could further endanger the patient's life. The liver has a tendency to compensate parenchymal loss until the utmost limit is reached. A patient with liver failure would not tolerate well further removal of liver mass even for starting a cell culture process; (iv) Autologous or allogeneic hepatic adult stem cells, or precursor cells could serve as an alternative cell source, but it will be necessary to differentiate them into functional mature hepatocytes in vitro and cultivate them in the relevant number ($1-2 · 10 10 cells) required for a liver support system without a loss of differentiation potential. No data on the successful ex vivo expansion of stem cells have been reported elsewhere in the literature. Furthermore, factors, such as medium formulations, supplementation of certain growth factors, as well as the microenvironment (He et al. 2003; Lowes et al. 2003; Semino et al. 2003; Suzuki et al. 2003) , are decisive for the differentiation of adult stem cells into mature hepatocytes in vitro, and are accompanied by the high cost; (v) In contrast to the adult stem cells, foetal hepatocytes have high mitotic rates independent of endogenous stimuli and therefore could be an ideal cell source for allogeneic liver cells in the future. However, the risk of tumorigenicity, incomplete differentiation and ethic concerns may limit their clinical application in the next years.
Maintenance of liver-specific functions in vitro and cell proliferation
Maintaining differentiated hepatocyte functions in vitro, in particular in extracorporeal liver support systems, remains a challenge. The sufficient conditions necessary for long-term stability of hepatocyte functions are still being optimized. Hepatocytes lose their metabolic activities within a short period of time in vitro due to the deprivation of their original architecture and polarity (Nyberg et al. 1992b ). The state of hepatocytes can be modulated by factors, such as cytokines and cellular contacts, as well as by the extracellular matrix (Isom et al. 1985; Ben-Ze'ev et al. 1988) . Since a complex extracellular matrix is necessary to maintain long-term differentiated hepatocytes in vitro there has been greater interest in developing effective three-dimensional systems that mimic the in vivo environment. It is well known that the extracellular matrix modulates the expression of liver-specific genes, including that of albumin, cytochromes P450, and transferrin (Schuetz et al. 1988; Saad et al. 1993) . In contrast to a single layer of hydrated rat tail tendon collagen gel, the sandwiching of rat hepatocytes between two collagen gel layers preserves a variety of liver-specific functions (Dunn et al. 1991 (Dunn et al. , 1992 . A recent study using rat hepatocytes has demonstrated that ECM remodeling in response to cytokines induces cell proliferation, an important parameter of liver regeneration (Serandour et al. 2005) . In vivo, these cytokines are produced by non-parenchymal hepatic cells in the regenerative process after hepatic injury or hepatectomy (Michalopoulos and DeFrances 1997; Ramadori and Armbrust 2001) . This process requires proliferation of hepatocytes and non-parenchymal hepatic cells to restore damaged liver-specific functions and/or the liver mass (Kang et al. 2004) . A cross-talk between these two cell types is not only important for cell proliferation but also for the maintenance of the differentiated stage of hepatocytes. This is perhaps one of the reasons why hepatocytes in co-cultures exhibit elevated metabolic activities over a long period of time compared to those in single cultures (Auth et al. 1998) . Proliferation of hepatocytes is initiated by cytokine-mediated G 0 /G 1 -transition of the cells, while the G 1 /S-transition is also controlled by hormones (Costa et al. 2003; Taub 2004) . Due to the involvement of certain cytokines and hormones in controlling the state of hepatocytes, the use of these components as medium supplements for the in vitro hepatocyte cultivation is an important aspect. A further aspect in liver regeneration after partial hepatectomy is the shear stress (Sato et al. 1999; Braet et al. 2004) . A possible relation between elevated blood flow associated with partial hepatectomy has been suggested. However, the influence of the shear stress on triggering further events, leading to hepatocyte proliferation, has only been proven in vivo (Schoen et al. 2001 ).
Bioartificial liver support systems
A large number of liver support systems have been developed to promote cell organization with the aim of providing in vivo conditions. These systems include the flat membrane configuration, arrangement of membranes in fibers (hollow fiber system), the encapsulation technology and cell aggregates, and they vary greatly with respect to their microenvironment. Table 1 summarizes the bioreactor designs that have been proposed and studied.
Flat membrane systems
Cultivation of isolated hepatocytes on a single gel has been shown to be ineffective since the cells lose their metabolic abilities within a short period in culture. Three-dimensional cell adhesion cultures on an extracellular matrix provide an alternative technique (Bucher et al. 1990 ). Among the first cultivation systems were cultures with rat hepatocytes entrapped in collagen gel (a sandwich configuration) or on a reconstituted basement membrane gel (Schuetz et al. 1988; Dunn et al. 1989) . The flat membrane bioreactor allows a high-density hepatocyte culture under sufficient oxygenation conditions closely corresponding to the in vivo microenvironment (De Bartolo and Bader 2001) . In this system porcine hepatocytes are co-cultured with non-parenchymal hepatic cells within an extracellular matrix between oxygen-permeable flat-sheet polymeric membranes as individual plates, thereby enabling the cells to remain polarized in vitro and maintaining constant liver-specific functions. A microporous polytetrafluoroethylene membrane that separates the cell compartment from the medium compartment protects the cells from shear forces and controls transfer of metabolites during continuous flow (Figure 2) . One of the prerequisites we have demanded for the flat membrane bioreactor, was thorough biochemical testing. In this context, our studies have shown that in vivo-like quantitative as well as qualitative performance could be achieved in vitro using pharmaceutical drugs as test candidates (Bader et al. 1992 (Bader et al. , 1996 (Bader et al. , 1998 Langsch and Bader 2001) . Currently, rat and human hepatocytes are being successfully cultured on novel modified polyetheretherketone membranes Nyberg et al. (1992a Nyberg et al. ( , c, 1993 Nyberg et al. ( , 1996 Nyberg et al. ( , 1999 Pig Immunoisolation pig, rabbit, rat Jauregui et al. (1994 Jauregui et al. ( , 1995 Protection against viral infection in humans by xenogeneic cells Gerlach (1996) In vivo-like microenvironment Ellis et al. (1996) Protection from shear stress Flendrig et al. (1997 Flendrig et al. ( , 1999 Ease of scale-up (PEEK-WC and PEEK-WE-polyurethane) which have been proposed to be promising biomaterials in liver support systems (De Bartolo et al. 2004 ). The use of a flat membrane bioreactor as an extracorporeal liver support system, however, is accompanied by some disadvantages, such as the potential large dead volume and the low surface area-to volume ratio, as well as providing limited protection against viral infection by xenogeneic cells (depending on the molecular weight cut-off of the membranes used). Nonetheless, improvements of these factors will allow its use in a clinical setting in the near future.
Hollow fiber systems
The development of hollow fiber technology allows for human or animal hepatocytes to become an integral part of a bioartificial liver support system and potentially increases clearance efficiency of an ex vivo method. The cells in hollow fibers are separated from blood or plasma by a semipermeable membrane with a defined molecular weight cut-off. The cylindrical form and small size of the hollow fibers limits the diffusion distance which separates the cells from the surrounding medium. Animal or human hepatocytes are cultured outside the lumen of fiber membranes (extrafiber space), while blood, plasma or culture medium is pumped through the fiber lumen (Sussman and Kelly 1993; Jauregui et al. 1994 ) (Figure 3a) . In contrast, Nyberg et al. have suspended rat hepatocytes in a three-dimensional gel which was injected into the intrafiber space of hollow fibers in a perfused bioreactor (Nyberg et al. 1992c) (Figure 3b ). To meet hepatocyte demands on their environment and their need for oxygen, a bioreactor incorporating design concepts of a hollow fiber oxygenator (OXY-HFB) was built (Jasmund et al. 2002) . Alternatively, a bioreactor has been constructed that consists of a spirally wound, nonwoven polyester matrix in a cartridge for hepatocyte immobilization and aggregation, and of integrated hollow fibers for low metabolite gradients, decentralized oxygenation, and CO 2 removal (Flendrig et al. 1997) . Medium or plasma is in direct contact with the hepatocytes by perfusion through semipermeable membranes. Hollow fiber membranes with different nominal molecular weight cut-offs (<400 kD) were tested for immunoprotection of xenogeneic hepatocytes and as viral barriers against PERV (Nyberg et al. 1992a (Nyberg et al. , 1999 . Studies on the use of polymeric semipermeable membranes, such as polycarbonate and cellulose acetate membranes, as well as of nonwoven polyurethane-based biomatrices in microfibers to support hepatocyte adhesion and metabolic functions, and to serve as immunoselective barriers in liver support systems, seem to be promising (Pahernik et al. 2001; De Bartolo et al. 2002) . Very recently, new polymeric semipermeable membranes used in biomedical devices for optimal detoxification and oxygenation of blood were the subject of investigation (Curcio et al. 2005) . Although most capillary hollow fiberbased liver support designs provide an effective immunoprotection, they have some inherent physical limitations with respect to total diffusion surface area and capacity for hepatocyte mass.
Encapsulation technology
Direct contact of xenograft cells with plasma or blood is known to elicit a host immune response. Microencapsulation technology has, therefore, been developed to provide sufficient isolation of xenogeneic cells from the recipient's immune system within a support system. This technique is based on the encapsulation of xenogeneic hepatocytes with a biomaterial that allows nutrients, oxygen, and stimuli to cross the semipermeable material, while components of the immune system are excluded (Orive et al. 2003) . Several biomaterials have been tested for their immune-and biocompatibility (Lacik et al. 1998; Honiger et al. 2000; Muraca et al. 2000; Quek et al. 2004) . Polyanionic alginate, a polysaccharide with gel forming properties, is composed of mannuronic acid (M) and guluronic acid (G), and is commonly applied in combination with polycationic poly-Llysine (PLL) for immunoprotection (Orive et al. 2004) . As the biocompatibility (host inflammatory response by induction of the fibrotic reaction to capsules, porosity, stability, and PLL-binding of capsules) of alginate capsules strongly depends on the G/M-ratio of the alginate applied, the alginate was enzymatically modified to improve the biocompatibility of alginate/PLL microcapsules (King et al. 2003) . It has been suggested that immune response is also reduced by applying alginates with a lower G-content and by introducing alginates with a high degree of purity (De Vos et al. 1997) . Other systems of encapsulation involve the replacement of PLL with poly-L-ornithine (PLO), chitosan, or agarose, resulting in improved biocompatibility or in increased mechanical stability (Uludag et al. 2000; Orive et al. 2004 ). Entrapment of rat or pig hepatocytes within coated alginate beads enables the cells to maintain their long-term metabolic functions (Miura et al. 1988; Joly et al. 1997) (Figure 4 ). This technique used in liver support systems benefits from the presence of a three-dimensional hepatic environment in combination with an optimal volume-surface ratio of capsules which guarantees to meet hepatocyte demand for nutrients and oxygen (Legallais et al. 2000) . Co-encapsulation of hepatocytes with nonparenchymal hepatic cells leads to the increased metabolic activity of hepatocytes, an observation which can be explained by the cytokine-release and ECM-production by non-parenchymal cells (Stange and Mitzner 1996) . Improvements of the liver-specific functions can also be achieved by co-encapsulation of hepatocytes with ECM components (Babensee et al. 1992; Quek et al. 2004; Seo et al. 2005) . Very recently, mouse hepatocytes Figure 3 . The diagram depicts two schemes of hollow fibers. (a) Hepatocytes are cultured on the extracapillary side of the semipermeable fibers while blood, plasma or medium flows through the lumen. The scheme is based on a system described by Sussman et al. (1992) . (b) Hepatocytes are embedded in a gel injected into the intrafiber space of hollow fibers as described by Nyberg et al. (1992a) . Blood or plasma perfuses between the hollow fibers, while medium flows through the fiber lumen.
attached to xyloglucan, a synthetic extracellular matrix, were embedded in alginate capsules, demonstrating enhanced metabolic functions in such a three-dimensional space (Seo et al. 2005) . Fremond et al. have shown that encapsulated hepatocytes in a bioreactor represent an effective model for bioartificial liver support systems (Fremond et al. 1993) . The application of a fixed bed bioreactor is, however, associated with the problem of channels forming which prevent a uniform flow around the capsules, possibly inducing a high level of shear stress which can release the cells from the capsules (Dore and Legallais 1999) . A more successful model is the current use of a dynamic (fluidized bed) bioreactor in which the diffusion coefficient of a compound tested is much higher than under batch (static) conditions (David et al. 2004 ).
Aggregate culture
Spherical aggregates (spheroids) of hepatocytes have been histologically shown to hold a threedimensional structure with a bile canaliculus-like network. These cells resume cell-cell contacts by being prevented from attaching to the substratum, they retain many morphological in vivo hepatic characteristics, and thereby maintain viability and metabolic functions to a greater extent and a longer period of time than those in monolayer cultures (Tong et al. 1994) . A range of methods has been developed for the generation of spheroids from animal hepatocytes, including non-adherent substratum, e.g. a neutral charge polymer poly(2-hydroxyethyl methacrylate (pHEMA) for self assembly, and spinner flasks (Koide et al. 1990; Sakai et al. 1996) (Figure 5 ). Hetero-spheroids of hepatocytes and non-parenchymal hepatic cells on a synthetic polymer were shown to further enhance long-term liver functions (Yamada et al. 2001) . Moreover, Michalopoulos et al. have suggested using the hepatocyte organoid (composed of proliferating hepatocytes and non-parenchymal hepatic cells) culture technique that a combination of certain cytokines, such as hepatocyte growth factor (HGF) and epidermal growth factor (EGF), and dexamethasone plays a role in the formation and structure of the in vivo-like architecture of hepatocytes (Michalopoulos et al. 2001) . Although hepatocytes in spheroids possess improved liverspecific functions and prolonged differentiated cell state in vitro, a concern is to be expressed regarding the size of the spheroids (Glicklis et al. 2004 ). Increasing spheroid size was found to induce cell necrosis due to the limited mass diffusion of oxygen and nutrients. A maximal level of oxygen consumption and albumin secretion by viable hepatocytes was reached in 100-lm diameter hepatic spheroids. More recently, a device composed of microstructured scaffolds was developed for the formation of small rat liver cell aggregates and was found to sustain hepatic metabolic functions for several days (Eschbach et al. 2005) . Disadvantages of the direct use of spheroids in a bioartificial liver system include the absence of an immunological isolation and the possible embolization of hepatocytes or non-parenchymal cells escaping from organoids into the system. Thus, hepatocyte aggregates are mostly immobilized in hollow fibers for the construction of a bioreactor (Lorenti et al. 2003; Gan et al. 2005) .
Logistics of bioartificial liver support systems
Cryopreservation of hepatocytes allows the possible application of the cells for short-term support of patients with hepatic failure, it avoids the costs of long-term hepatocyte culture, and reduces the risk of contamination that exists during prolonged cell culture. However, cryopreservation of hepatocytes is associated with decreased cell functional activities and increased cell apoptosis (Guillouzo et al. 1999; Hengstler et al. 2000) . It has been suggested that inhibition of proteins involved in apoptosis protects the cells from this process and preserve their viability after cryopreservation (Matsushita et al. 2003) . Another method to reduce injury to hepatocytes during the cryopreservation step is to encapsulate the cells before cryopreservation (Dixit et al. 1993) . These cells were shown to survive the procedure, maintaining their viability and metabolic functions (Canaple et al. 2001) . While hepatocyte spheroids can be cryopreserved in defined solution (Lee et al. 2004) , the use of the cryopreservation technique is limited in hollow fiber systems (unpublished observation). In contrast, flat membrane plates covered with a cryoprotective solution are completely cryopreservable (unpublished observation). All techniques discussed in this article have advantages in the large scale bioreactors for liver support systems due to their easy upscaling (Gerlach et al. 1993; Flendrig et al. 1997; De Bartolo and Bader 2001; Sauer et al. 2001) . Systems using hepatic spheroids and encapsulated hepatocytes can easily be scaled to the cell mass needed to sustain the patient's life but may be associated with the possible dead volume and limitations of the mass transfer. Available space and flexible transportation are concerns which have arisen due to the unlimited upscaling of flat or stacked plate designs and hollow fiber devices.
Creation of a duty-service cell laboratory in specialized liver support centers should meet the frequency of treating patients with liver failure by providing ready-to-use liver support systems. The availability of such systems will improve the survival rate in patients by serving as a bridge to transplantation and to liver regeneration.
Liver support systems in preclinical and clinical test
The classical non-biological dialysis and filtration methods of liver support could decrease mortality in patients with moderate liver failure. However, these approaches have met with limited success due to their partial replacement of liver-specific functions, i.e. detoxification. Because of the diverse function of the liver, biological liver support systems have been constructed that rely on the functionality of hepatocytes from xenogeneic or human origin. Various liver support systems have been preclinically and clinically examined for their in vivo performance to date. In preclinical testing with liver support systems, significant improvement of survival time in hepatectomized animals or animals with moderate to severe liver failure could be achieved (Jauregui et al. 1995; Dixit and Gitnick 1998; Flendrig et al. 1999; Shito et al. 2003; Yamashita et al. 2003; Fruhauf et al. 2004) . However, it is difficult to assess and compare the efficacy of these systems, in part because of the heterogeneity of the animal models used. Several liver support devices based mainly on the capillary hollow fiber system, have entered a Phase I/II clinical safety evaluation. Among them are the extracorporeal liver assist device (ELAD), the bioartificial liver support system (BLSS), the liver support system (LSS), the modular extracorporeal liver support (MELS), The Academic Medical Center bioartificial liver (AMC-BAL), the HepatAssist, and the radial flow bioreactor (RFB). The ELAD uses a human hepatoma cell line C3A grown in the extracapillary space of hollow fiber capillaries (Sussman et al. 1992 ). The patient's blood flows through the cartridge. Despite its high production of albumin and a-fetoprotein the C3A cells do not sufficiently express some specific functions such as ammonia detoxification and ureagenesis (Hoekstra and Chamuleau 2002) . In a pilot-controlled clinical trial, the median period of the ELAD treatment was 72 h, but there was no significant difference in the survival rate between the ELAD-treated patients and the controls (Ellis et al. 1996) . The BLSS system uses primary porcine hepatocytes and perfuses whole blood through the bioreactor. The cells mixed with collagen are infused into the extracapillary space of fibers. Following the 12-h treatment, PERV transmission from the animal cells to patients was not observed (Mazariegos et al. 2001; Kuddus et al. 2002) . Survival outcome has not been reported for this system. The MELS consists of the CellModule (the LSS), a multi-compartment bioreactor loaded with primary human hepatocytes, that are obtained from discarded donor livers, combined, if required, with a DetoxModule for albumin dialysis and a DialysisModule for continuous veno-venuous hemofiltration . The overall treatment time ranged between 7 and 144 h, and all patients survived until transplantation . The AMC-BAL is based on a bioreactor with an integral oxygenator and a spirally wound matrix for small aggregates of primary porcine hepatocytes (van de Kerkhove et al. 2005b ). The particular feature of this system is the direct contact of the patient's plasma with the cells, resulting in an optimal mass transfer and direct oxygenation. The maximal AMC-BAL treatment was 24 h with no PERV transmission from animal cells to the patients and a 100% survival rate in a small number of patients used in this study until transplantation.
The HepatAssist system has been tested in the largest controlled clinical trial involving 171 enrolled patients (Demetriou et al. 2004 ). This liver support system is comprised of cryopreserved primary porcine hepatocytes in the extracapillary space of fibers of the bioreactor. The plasma of the patient flows through the capillary lumen. Treatment time was 6-8 h with no evidence of viral transmission from the porcine cells to the patients. Improved survival was only found in the liver support system-treated patients with fulminant/ subfulminant hepatic failure compared with the controls. However, when considering the entire patient population enrolled in this study the difference in 30-day survival was not statistically significant. In the RFB system, primary porcine hepatocytes are entrapped within woven-nonwoven polyester fabric (Morsiani et al. 2001) . Treatment lasted 6-24 h and was well tolerated in patients. PERV transmission was not detected during the short-term follow-up (Morsiani et al. 2002b) . Amelioration of the neurologic status was only observed in patients during treatment with the HepatAssist, the AMC-BAL, the RFB, and the MELS system. Kjaergard et al. conducted an analysis of the published clinical trials that used a variety of artificial and bioartificial liver support systems for acute and acute-on-chronic liver failure up to September 2002 (Kjaergard et al. 2003) . A total of 483 patient outcomes (353 and 130 patients with acute and acute-on-chronic liver failure, respectively) from 12 randomized trials were assessed. It was concluded that these systems had no effect on mortality in patients with acute liver failure, but a 33% reduction in mortality was seen in patients with acute-on-chronic liver failure. A challenge in the development of a liver support device is the reality that good trials are difficult to design and execute.
The variability in devices and cells, setup of the treatments, patients, and in the outcome parameters used makes it difficult to compare the clinically applied liver support systems. The small number of clinical studies performed thus far are not sufficient to draw definitive conclusions with respect to improvements in the therapy of patients with acute or acute-on-chronic liver failure. Clear aetiology of liver disease should also be considered in the choice of the liver support systems available. Therefore, more complete characterization of the safety and efficacy of the BAL systems requires completion of the Phase I/II safety/efficacy evaluation.
Future perspectives
Multiple hepatocyte culture models and bioreactor constructions are currently available for the development of liver support systems. Although their results collected in many experimental and clinical trials are encouraging, the field is still in its initial stages. Their future use will depend on the choice and stabilization of the cellular component. Thus, a better understanding of hepatocyte-matrix interactions, flow and mass transport across membranes and biomaterials, and host response is still required and will probably result in the development of a new generation of liver assist devices. In addition, immunological problems with the use of xenogeneic hepatocytes and some characteristic differences between human and animal hepatocytes may necessitate the use of allogeneic materials. Their limited availability has led to the potential application of hepatic stem cells in liver support systems and in liver regeneration. Stem cell research is currently one of the most important fields and its application in tissue engineering bodes well for the future.
Alternatively, the development of bioartificial tissues has also made progress in a number of fields. We have focused on the development of bioreactors in the field of cardiovascular, bone, cartilage, and skin. Such bioreactors are designed for the use of autologous cells and for generating an implant. In contrast, a liver bioreactor is a hybrid device aimed at bridging to transplantation or ideally to autologous liver regeneration. The limited access to autologous liver tissue and the preferred scenario of autologous liver regeneration without transplantation substantiate this concept further. We use primary liver cells and focus on identifying the mechanisms of liver regeneration in vivo with the aim of replicating these in vitro. Once such mechanisms are elucidated and used for therapeutic reasons in vitro or in vivo, the next generation of liver support systems will enter the stage of preclinical and clinical testing and thereby overcome the current stagnation in the field.
